Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Primary Progressive Multiple Sclerosis
View Full LandscapeTarget Indication
Primary Progressive Multiple Sclerosis
Clinical Trial
NCT04458051Last updated: 12/7/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Cenrifki
Cenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.
View on EMA